{"id":"W4405096042","doi":"10.1182/blood-2024-200319","title":"HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Chugai Pharmaceutical; Genentech; Swedish Orphan Biovitrum; Eisai; Sierra Oncology; CTI Biopharma; Incyte; Novartis Pharma; Otsuka Pharmaceutical; Astellas Pharma; Ariad Pharmaceuticals; MorphoSys; Celgene; Gilead Sciences; Meiji Seika Pharma; AOP Orphan; Torii Pharmaceutical; Bristol-Myers Squibb","keywords":"Myelofibrosis; Medicine; Placebo; Internal medicine; Randomized controlled trial; Phases of clinical research; Double blind; Clinical trial; Oncology; Alternative medicine; Pathology; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239522,0.002143672,0.003311811,0.0005889806,0.000655882,0.00121338,0.001136729,0.002161455,0.01086416],"category_scores_gemma":[0.001665202,0.0009016611,0.002431108,0.000397588,0.001411223,0.001453281,0.0005495454,0.003779609,0.001353152],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007559609,"about_ca_system_score_gemma":0.00159075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006313229,"about_ca_topic_score_gemma":0.001594199,"domain_scores_codex":[0.9993856,0.000276316,0.00003511761,0.0001309722,0.00006976754,0.0001021308],"domain_scores_gemma":[0.9991425,0.000180918,0.000210035,0.00005754952,0.00006813358,0.0003408586],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9657764,0.01441044,0.000505569,0.0008628087,0.0008288289,0.00005477538,0.00004436361,0.0001852698,0.002401135,0.0001864895,0.001551859,0.01319204],"study_design_scores_gemma":[0.9519414,0.04584711,0.0009032137,0.00003259821,0.0002157105,0.0000296286,0.00001061797,0.0002106251,0.000151564,0.0001562514,0.0004900307,0.00001116184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9494954,0.0122021,0.002559609,0.002129731,0.001570499,0.02166392,0.004044262,0.000670513,0.00566394],"genre_scores_gemma":[0.9520739,0.004934009,0.005751234,0.004014222,0.0009524956,0.0243269,0.002939163,0.00007652981,0.004931593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01086416,"threshold_uncertainty_score":0.03634429,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01651577286164992,"score_gpt":0.2874387472039899,"score_spread":0.27092297434234,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}